Study of XB010 in Subjects With Solid Tumors (NCT06545331)
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Who can join: Review the eligibility criteria below.
Location: City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
- Georgetown University Medical Center — Washington D.C., District of Columbia
- Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida
- Winship Cancer Institute — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- Siteman Cancer Center — St Louis, Missouri
- Montefiore Medical Center - Montefiore Medical Park — The Bronx, New York
- Carolina BioOncology Institute — Huntersville, North Carolina
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- SCRI Oncology Partners — Nashville, Tennessee
- NEXT Austin — Austin, Texas
- Baylor University Medical Center — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Inova Schar Cancer — Fairfax, Virginia
- NEXT Virginia — Fairfax, Virginia
- University Hospitals of Leicester NHS Trust — Leicester,
- Sarah Cannon Research Institute London — London,
- University College London Hospitals NHS Foundation Trust — London,
- The Christie NHS Foundation Trust — Manchester,
📞 Contact the Study Coordinator
Phone: 1-888-EXELIXIS (888-393-5494)
Email: druginfo@exelixis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced or Metastatic Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors — San Francisco, California
- PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors — Beverly Hills, California
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors — Los Angeles, California
- A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors — San Diego, California
Explore by condition: All Locally Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.